JP2004514723A - Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体 - Google Patents

Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体 Download PDF

Info

Publication number
JP2004514723A
JP2004514723A JP2002546552A JP2002546552A JP2004514723A JP 2004514723 A JP2004514723 A JP 2004514723A JP 2002546552 A JP2002546552 A JP 2002546552A JP 2002546552 A JP2002546552 A JP 2002546552A JP 2004514723 A JP2004514723 A JP 2004514723A
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
amino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002546552A
Other languages
English (en)
Japanese (ja)
Inventor
リン，　コ−チャン
ヴ，　チ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of JP2004514723A publication Critical patent/JP2004514723A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2002546552A 2000-12-01 2001-11-30 Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体 Pending JP2004514723A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009278047A Division JP2010053148A (ja) 2000-12-01 2009-12-07 Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体

Publications (1)

Publication Number Publication Date
JP2004514723A true JP2004514723A (ja) 2004-05-20

Family

ID=22948640

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002546552A Pending JP2004514723A (ja) 2000-12-01 2001-11-30 Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体
JP2009278047A Withdrawn JP2010053148A (ja) 2000-12-01 2009-12-07 Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009278047A Withdrawn JP2010053148A (ja) 2000-12-01 2009-12-07 Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体

Country Status (33)

Country Link
US (2) US6605601B2 (de)
EP (1) EP1347981B1 (de)
JP (2) JP2004514723A (de)
KR (1) KR20040011439A (de)
CN (1) CN100497340C (de)
AR (1) AR035400A1 (de)
AT (1) ATE394402T1 (de)
AU (2) AU1997702A (de)
BG (1) BG107849A (de)
BR (1) BR0115833A (de)
CA (1) CA2430508C (de)
CZ (1) CZ20031513A3 (de)
DE (1) DE60133931D1 (de)
EA (1) EA009814B1 (de)
EE (1) EE200300260A (de)
ES (1) ES2305139T3 (de)
GE (1) GEP20094697B (de)
HK (1) HK1059927A1 (de)
HU (1) HUP0400530A3 (de)
IL (1) IL156046A0 (de)
IS (1) IS6821A (de)
MX (1) MXPA03004857A (de)
MY (1) MY127120A (de)
NO (1) NO20032483L (de)
NZ (1) NZ526511A (de)
PL (1) PL362642A1 (de)
SK (1) SK6552003A3 (de)
TR (1) TR200300766T2 (de)
TW (1) TWI293301B (de)
UA (1) UA75625C2 (de)
WO (1) WO2002044182A1 (de)
YU (1) YU42903A (de)
ZA (2) ZA200304067B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60018216T2 (de) * 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
EA009814B1 (ru) * 2000-12-01 2008-04-28 Байоджен Айдек Ма Инк. Конденсированные производные пурина как антагонисты рецепторов аденозина а
EP1601649A4 (de) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosinrezeptorantagonisten
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
JPWO2004096812A1 (ja) * 2003-04-25 2006-07-13 協和醗酵工業株式会社 縮合ピリミジン誘導体
RU2367442C2 (ru) * 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
US20080161327A1 (en) * 2005-03-11 2008-07-03 Aderis Pharmaceuticals, Inc. Substituted 9-Alkyladenines and the Use Thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
EP2018380B1 (de) 2006-05-19 2011-10-19 Abbott Laboratories CNS-aktivierte kondensierte bi- und heterocyclisch substituierte azabicyklische Alkanderivate
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
BRPI0713619A2 (pt) 2006-06-23 2013-01-15 Incyte Corp composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto.
WO2007150026A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CN111770926B (zh) * 2018-01-04 2023-07-21 因佩蒂斯生物科学有限公司 三环化合物、组合物及其医药应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE69033614T2 (de) * 1989-10-20 2001-04-19 Kyowa Hakko Kogyo Kk Kondensierte Purinderivate
SG52496A1 (en) 1991-09-23 1998-09-28 Univ Florida State Preparation of substituted isoserine esters using metal alkoxides and beta-lactams
AU4471297A (en) * 1996-10-07 1998-05-05 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
AU740770B2 (en) * 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
ES2284256T3 (es) * 1998-07-02 2007-11-01 Kyowa Hakko Kogyo Co., Ltd. Medicamentos para la diabetes.
DE60018216T2 (de) * 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
EA009814B1 (ru) * 2000-12-01 2008-04-28 Байоджен Айдек Ма Инк. Конденсированные производные пурина как антагонисты рецепторов аденозина а

Also Published As

Publication number Publication date
EP1347981A1 (de) 2003-10-01
NZ526511A (en) 2005-04-29
US7022686B2 (en) 2006-04-04
EP1347981B1 (de) 2008-05-07
NO20032483D0 (no) 2003-06-02
GEP20094697B (en) 2009-06-10
TWI293301B (en) 2008-02-11
EE200300260A (et) 2003-08-15
ATE394402T1 (de) 2008-05-15
HUP0400530A3 (en) 2007-05-29
BG107849A (bg) 2004-01-30
IS6821A (is) 2003-05-20
JP2010053148A (ja) 2010-03-11
CA2430508A1 (en) 2002-06-06
US20030220358A1 (en) 2003-11-27
US20020111333A1 (en) 2002-08-15
YU42903A (sh) 2006-05-25
CN1481387A (zh) 2004-03-10
TR200300766T2 (tr) 2004-09-21
SK6552003A3 (en) 2003-12-02
EA200300629A1 (ru) 2003-12-25
MY127120A (en) 2006-11-30
CN100497340C (zh) 2009-06-10
CZ20031513A3 (cs) 2003-09-17
HK1059927A1 (en) 2004-07-23
BR0115833A (pt) 2003-10-28
MXPA03004857A (es) 2003-08-19
ES2305139T3 (es) 2008-11-01
KR20040011439A (ko) 2004-02-05
ZA200304067B (en) 2005-05-30
WO2002044182A1 (en) 2002-06-06
AU1997702A (en) 2002-06-11
EA009814B1 (ru) 2008-04-28
DE60133931D1 (de) 2008-06-19
US6605601B2 (en) 2003-08-12
PL362642A1 (en) 2004-11-02
IL156046A0 (en) 2003-12-23
AR035400A1 (es) 2004-05-26
ZA200408755B (en) 2005-07-27
AU2002219977B2 (en) 2008-01-24
UA75625C2 (en) 2006-05-15
NO20032483L (no) 2003-07-30
CA2430508C (en) 2010-05-18
HUP0400530A2 (hu) 2004-06-28

Similar Documents

Publication Publication Date Title
JP2010053148A (ja) Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体
AU2002219977A1 (en) Condensed purine derivatives as A1 adenosine receptor antagonists
US20080004293A1 (en) Adenosine receptor antagonists and methods of making and using the same
BG65720B1 (bg) Полициклоалкилпурини, антагонисти на аденозин рецептор
JPS61236778A (ja) ５−置換ピラゾロ〔４，３−ｄ〕ピリミジン−７−オン
JPH05213940A (ja) 新規なベンゾピラン誘導体
HU212311B (en) Process for producing pharmaceutical compositions containing pirimidone derivatives in the treatment of certain airway or skin diseases
KR20090042330A (ko) 혈액뇌장벽을 통과하지 않는 ｋｗ―３９０２ 컨쥬게이트
US20230381174A1 (en) Thionoester-derivative of rabeximod for the treatment of inflammatory and autoimmune disorders
JPS60142968A (ja) 新規ジアジン−エテニルフエニルオキサミン酸
US20220380370A1 (en) Xanthine cb1 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090303

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091207